Core Insights - The company has selected its first oral glucagon-like peptide-1 (GLP-1) receptor agonist, ASC36 oral tablets, for clinical development, with plans to submit an Investigational New Drug (IND) application to the FDA in Q2 2026 [1] Group 1: Drug Development - ASC36 oral tablets are developed using the proprietary oral peptide delivery enhancement technology (POTENT) [1] - In non-human primates, the absolute oral bioavailability of ASC36 was 8% for the 10 mg dose and 6% for the 25 mg dose, with elimination half-lives of 116 hours and 167 hours respectively, supporting once-daily dosing [1][2] - ASC36 demonstrated significant weight loss effects in both non-human primates and diet-induced obesity (DIO) rat models, achieving up to a 13.2% reduction in average body weight relative to baseline after 7 days of treatment [2] Group 2: Competitive Advantage - In head-to-head comparisons with other GLP-1 receptor agonists, ASC36 achieved weight loss effects that were approximately 32% and 91% better than eloralintide and petrelintide respectively [2] - The potential for superior oral bioavailability and efficacy may allow for lower dosing of ASC36 compared to recently FDA-approved GLP-1R agonists, which could lead to cost advantages in manufacturing [2] - The company has developed ASC36 using its Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) technology, contributing to a competitive and diversified product pipeline aimed at addressing diverse treatment needs for obesity and other metabolic diseases [3]

Core Viewpoint - The company, Gilead Sciences-B (01672.HK), has selected its first oral glucagon-like peptide-1 receptor agonist, ASC36 oral tablets, for clinical development, with plans to submit an Investigational New Drug (IND) application to the FDA in Q2 2026 for obesity treatment [1][2] Group 1 - ASC36 oral tablets have shown an absolute oral bioavailability of 6% to 8% in non-human primate studies, utilizing Gilead's proprietary oral peptide delivery enhancement technology (POTENT) [1] - In non-human primates, ASC36 oral tablets led to an average weight reduction of up to 13.2% relative to baseline after 7 days of once-daily dosing, significantly reducing food intake [1] - In a head-to-head study using a diet-induced obesity (DIO) rat model, ASC36 demonstrated weight loss effects that were approximately 32% and 91% greater compared to eloralintide and petrelintide, respectively [1] Group 2 - The company has three key glucagon-like peptide-1 candidates: oral small molecule GLP-1, oral GLP-1 peptide, and monthly subcutaneous GLP-1 peptide, with ASC36 oral tablets being a significant GLP-1 agonist [2] - Gilead's competitive and differentiated product pipeline is supported by three proprietary technology platforms: AISBDD, Ultra-Long-Acting Platform (ULAP), and POTENT, aimed at addressing diverse treatment needs for obesity and other metabolic diseases [2]

Core Viewpoint - The company, Gilead Sciences, has announced the selection of its first oral glucagon-like peptide-1 (GLP-1) receptor agonist, ASC36, for clinical development, with plans to submit an Investigational New Drug (IND) application to the FDA by Q2 2026 [1] Group 1: Drug Development and Clinical Trials - ASC36 oral tablets are developed using Gilead's proprietary oral peptide delivery enhancement technology (POTENT) [1] - The absolute oral bioavailability of ASC36 in non-human primates is 8% for the 10 mg dose and 6% for the 25 mg dose, with elimination half-lives of 116 hours and 167 hours respectively, supporting less frequent dosing [1][2] - The drug has shown significant weight loss effects in both non-human primates and diet-induced obesity (DIO) rat models, achieving up to a 13.2% reduction in average body weight relative to baseline after 7 days of treatment [2] Group 2: Comparative Efficacy and Manufacturing Advantages - ASC36 demonstrated approximately 32% and 91% greater weight loss compared to eloralintide and petrelintide, respectively, in head-to-head DIO rat models [2] - The potential for superior oral bioavailability and efficacy may allow for lower dosing compared to recently FDA-approved GLP-1R agonists, which could lead to cost advantages in large-scale production [2] - ASC36 is part of a broader pipeline of insulin candidates, including oral small molecule insulin and monthly subcutaneous insulin peptides, leveraging Gilead's three proprietary technology platforms: AI-assisted structure-based drug discovery (AISBDD), ultra-long-acting drug development platform (ULAP), and POTENT [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Ascletis Pharma Inc. 歌禮製藥有限公司 ASC36口服片由歌禮利用其專有的口服多肽遞送增強技術(POTENT)開發而成。 在非人靈長類動物中，10毫克ASC36口服片在每只動物中每日一次給藥，給藥7 天後，穩態下的絕對口服生物利用度(absolute oral bioavailability)[1]為8%，消除半 衰期(elimination half-life)達116小時；25毫克ASC36口服片在每只動物中每日一 1 － 在非人靈長類動物研究中，通過利用歌禮口服多肽遞送增強技術(POTENT)， ASC36口服片在穩態下的絕對口服生物利用度達6%至8%。 － 在非人靈長類動物中，ASC36口服片每日一次給藥7天後，使相對基線的平 均體重下降高達13.2%。ASC36片亦顯著減少了食物攝入。 － 在一項頭對頭飲食誘導肥胖(DIO)大鼠模型中，與eloralintide和petre ...

FF305 | | | B. 贖回/購回股份 (擬註銷但截至期終結存日期尚未註銷) (註5及6) | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1). | 購回股份擬註銷但尚未註銷 | | 150,000 | 0.0151 % | HKD | 6.4567 | | | 變動日期 | 2025年4月3日 | | | | | | 2). | 購回股份擬註銷但尚未註銷 | | 150,000 | 0.0151 % | HKD | 5.0924 | | | 變動日期 | 2025年4月7日 | | | | | | 3). | 購回股份擬註銷但尚未註銷 | | 100,000 | 0.0101 % | HKD | 4.8531 | | | 變動日期 | 2025年4月9日 | | | | | | 4). | 購回股份擬註銷但尚未註銷 | | 100,000 | 0.0101 % | HKD | 4.9125 | | | 變動日期 | 2025年4月10日 | | | | | | 5). | 購回股份擬註銷但尚未註銷 | | 100,000 | 0.010 ...

歌礼制药-B(01672)公布，已于2026年2月10日完成配售合共6925.6万股股份，每股配售价12.18港元，净 筹约8.35亿港元，约90%建议用于治疗肥胖症的小分子口服GLP-1受体激动剂ASC30的全球III期临床试 验的准备、基础工作及启动，约10%建议用作营运资金及其他一般公司用途。 ...

Core Viewpoint - Company completed the placement of a total of 69.256 million shares at a price of HKD 12.18 per share, raising approximately HKD 835 million, with 90% allocated for the global Phase III clinical trial preparation of the obesity treatment small molecule oral GLP-1 receptor agonist ASC30 [1] Group 1 - The placement was completed on February 10, 2026 [1] - Approximately 90% of the raised funds will be used for the preparation, groundwork, and initiation of the global Phase III clinical trial for ASC30 [1] - The remaining 10% of the funds is suggested for operational expenses and other general corporate purposes [1]

格隆汇2月10日丨歌礼制药-B(01672.HK)宣布，配售已于2026年2月10日完成。合共6925.6万股新股份已 按每股12.18港元的配售价成功配售予不少于6名承配人。 就配售而言，由于配售的所有条件已获达成，故合共6925.6万股配售股份已按每股12.18港元的配售价发 行予承配人。净配售价估计约为每股配售股份12.06港元。配售股份的数目占经配售扩大后公司股份(不 包括库存股份)的约6.53%。 公司配售所得款项总额约为8.435亿港元，而配售所得款项净额合共约为8.352亿港元。配售所得款项净 额中约90%建议用于治疗肥胖症的小分子口服GLP-1受体激动剂ASC30之全球III期临床试验的准备、基 础工作及启动，而配售所得款项净额中约10%建议用作营运资金及其他一般公司用途。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約，亦並非擬用作邀請提出 相關要約或邀請。本公告概不得直接或間接於美國境內或向美國境內派發。本公告並不構成亦 不組成在美國購買或認購證券的任何要約或招攬的一部分。本公告所述之本公司股份尚未且將 不會根據證券法登記，且除根據證券法登記規定獲豁免外，不得在美國提呈發售或出售。本公 告所述之本公司股份將(i)僅根據證券法第144A條獲豁免登記向合資格機構買家，及(ii)根據證 券法S規例於美國境外進行之離岸交易中提呈發售及出售。本公司無意於美國公開發售本公司 股份。 Ascletis Pharma Inc. 歌禮製藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1672） 就配售而言，由於配售的所有條件已獲達成，故合共69,256,000股配售股份已按 每股12.18港元的配售價發行予承配人。淨配售價（經扣除有關費用、成本及開支 後）估計約為每 ...

Market Overview - The Hong Kong stock market exhibited a "structural differentiation" trend on February 10, with a strong wait-and-see sentiment before the holiday. The Hang Seng Index rose by 0.58% to 27,183.15 points, the Hang Seng Tech Index increased by 0.62% to 5,451.03 points, the National Enterprises Index climbed by 0.81% to 9,242.75 points, and the Red Chip Index gained 0.27% to 4,407.29 points [1] Individual Stock Highlights - Evergrande Property saw a significant increase of 5.36% to 1.18 HKD, driven by news of potential bidders submitting updated offers for the company's assets, indicating progress in the liquidation process [2] - The stock of Geekplus Technology surged by 11.37% to 28.02 HKD following the launch of its Gino 1 warehouse robot, which is expected to accelerate the adoption of unmanned warehouses [3] - Yiteng Jiahe rose nearly 7% due to the completion of the first dosing in Phase II clinical trials for its ANGPTL3 siRNA drug EDP167 [4] - Bubble Mart received a favorable outlook from Macquarie, with a reiterated "outperform" rating, projecting global sales to exceed 400 million units by 2025 [5] Sector Performance - The AI and robotics sector emerged as a strong focus, with multiple stocks experiencing significant gains, including MiniMax-WP and Zhiyuan, which saw increases of 24% and 11%, respectively [3] - Pharmaceutical and technology hardware stocks also showed positive performance, with notable gains from companies like Singularity and Gree Medical, benefiting from favorable policy changes and strategic investments [4] Institutional Insights - Dongwu Securities noted that despite increased inflows from southbound funds, overall trading volume in the Hong Kong market has decreased, influenced by global tech stock capital expenditure concerns [6] - Analysts from Jianyin International indicated that the valuation recovery of Hong Kong stocks is nearly complete, shifting the investment logic from "valuation recovery" to "new productive forces" [6] - Analysts emphasized that the continuous inflow of southbound funds could enhance market sentiment and strengthen the pricing power of mainland funds in the Hong Kong market [6]